The Functional Landscape of SARS-CoV-2 3CL Protease

• Published in: bioRxiv
• Main Authors: Iketani, Sho, Seo Jung Hong, Sheng, Jenny, Bahari, Farideh, Culbertson, Bruce, Fereshteh Fallah Atanaki, Aditham, Arjun K, Kratz, Alexander F, Luck, Maria I, Tian, Ruxiao, Goff, Stephen P, Montazeri, Hesam, Sabo, Yosef, Ho, David D, Chavez, Alejandro
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 12.07.2022
• Subjects: Coronaviridae; Coronaviruses; COVID-19; Drug development; Mutation; Patent applications; Proteinase inhibitors; Severe acute respiratory syndrome coronavirus 2
• DOI: 10.1101/2022.06.23.497404

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) as the etiologic agent of COVID-19 (coronavirus disease 2019) has drastically altered life globally. Numerous efforts have been placed on the development of therapeutics to treat SARS-CoV-2 infection. One particular target is the 3CL protease (3CLpro), which holds promise as it is essential to the virus and highly conserved among coronaviruses, suggesting that it may be possible to find broad inhibitors that treat not just SARS-CoV-2 but other coronavirus infections as well. While the 3CL protease has been studied by many groups for SARS-CoV-2 and other coronaviruses, our understanding of its tolerance to mutations is limited, knowledge which is particularly important as 3CL protease inhibitors become utilized clinically. Here, we develop a yeast-based deep mutational scanning approach to systematically profile the activity of all possible single mutants of the SARS-CoV-2 3CLpro, and validate our results both in yeast and in authentic viruses. We reveal that the 3CLpro is highly malleable and is capable of tolerating mutations throughout the protein, including within the substrate binding pocket. Yet, we also identify specific residues that appear immutable for function of the protease, suggesting that these interactions may be novel targets for the design of future 3CLpro inhibitors. Finally, we utilize our screening results as a basis to identify E166V as a resistance-conferring mutation against the therapeutic 3CLpro inhibitor, nirmatrelvir, in clinical use. Collectively, the functional map presented herein may serve as a guide for further understanding of the biological properties of the 3CL protease and for drug development for current and future coronavirus pandemics. Competing Interest Statement S.I., D.D.H., and A.C. are inventors on patent applications related to the development of inhibitors against the SARS-CoV-2 3CL protease.